Arcturus Therapeutics Holdings (ARCT) EBIAT (2018 - 2025)
Arcturus Therapeutics Holdings (ARCT) has disclosed EBIAT for 8 consecutive years, with -$29.1 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 3.09% year-over-year to -$29.1 million, compared with a TTM value of -$65.8 million through Dec 2025, up 18.73%, and an annual FY2025 reading of -$65.8 million, up 18.73% over the prior year.
- EBIAT was -$29.1 million for Q4 2025 at Arcturus Therapeutics Holdings, down from -$13.4 million in the prior quarter.
- Across five years, EBIAT topped out at $117.3 million in Q4 2022 and bottomed at -$56.3 million in Q1 2021.
- Average EBIAT over 5 years is -$18.5 million, with a median of -$24.2 million recorded in 2022.
- The sharpest move saw EBIAT crashed 476.31% in 2021, then skyrocketed 403.51% in 2022.
- Year by year, EBIAT stood at -$38.7 million in 2021, then surged by 403.51% to $117.3 million in 2022, then plummeted by 109.98% to -$11.7 million in 2023, then crashed by 156.3% to -$30.0 million in 2024, then increased by 3.09% to -$29.1 million in 2025.
- Business Quant data shows EBIAT for ARCT at -$29.1 million in Q4 2025, -$13.4 million in Q3 2025, and -$9.2 million in Q2 2025.